Resources

In part 5 of this Exclusive Interview, Lisa Letourneau talks with Diabetes in Control Publisher Steve Freed about when medical professionals should reach out for help regarding diagnosing monogenic diabetes and the possible costs involved.

In part 6, the conclusion of this Exclusive Interview, Lisa Letourneau talks with Diabetes in Control Publisher Steve Freed about the effectiveness of various diabetes treatments on monogenic and how to get further information.

Medications suggested for second- and third-line treatments for diabetes management following treatment failure with metformin and sulfonylureas.

Patients with type 1 diabetes and prolonged increased HbA1c were found to be at two-times greater risk for dementia than those with well-managed HbA1c values.

Thorough knowledge of anti-diabetes medications found to lead to better management, adherence.

When combined with diet and exercise, GLP-1 medication showed significant weight loss compared to liraglutide and placebo, a new study finds.

New findings compare treatment with patients taking two or more glucose-lowering agents.

By Sheri R. Colberg, PhD, FACSM
It's known that lack of exercise, poor eating habits, genetics, and lifestyle factors can all contribute to the onset of prediabetes and type 2 diabetes. I have spent many years touting the benefits of lifestyle change to prevent and manage these health conditions—and in some cases reverse them. Exercise is a particularly important lifestyle management tool because of its ability to lower inflammation (the underlying cause of insulin resistance) naturally.

In your experience, what have most studies about CGM demonstrated?

- HbA1c is lower in CGM users regardless of age or type of insulin delivery.
- Patients using MDI + CGM have greater reductions in HbA1c than those using CSII + CGM.
- Reductions in glycemic variability and time spent in hypoglycemia are not significantly different between SAP and MDI/RT-CGM therapy groups.
- All of the above

Follow the link to see how you and your colleagues compare.

Which is not a side effect of SGLT-2 Inhibitors?

A. Kidney failure
B. Hyperkalemia
C. Ketoacidosis
D. Hypertension
E. Increased cholesterol levels
F. Serious urinary tract infections
G. Increased bladder cancer risk
H. Serious allergic reactions

Follow the link for the answer.